Icon is boosting its medical device and diagnostic research offering with a buyout deal for Parisian medtech CRO MedPass International. The deal, financial details of which were not disclosed ...

ICON's 2025 revenue guidance is $8.05 billion–$8.65 billion, a 1% growth midpoint, versus consensus $8.5 billion. Adjusted EPS for 2025 is forecasted at $13.00–$15.00, flat compared to 2024 ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is delivering ...